Samsung Pharm (001360) - Net Assets
Based on the latest financial reports, Samsung Pharm (001360) has net assets worth ₩180.09 Billion KRW (≈ $122.05 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩224.14 Billion ≈ $151.89 Million USD) and total liabilities (₩44.04 Billion ≈ $29.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Samsung Pharm asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩180.09 Billion |
| % of Total Assets | 80.35% |
| Annual Growth Rate | 9.74% |
| 5-Year Change | -13.17% |
| 10-Year Change | 128.94% |
| Growth Volatility | 40.53 |
Samsung Pharm - Net Assets Trend (2012–2024)
This chart illustrates how Samsung Pharm's net assets have evolved over time, based on quarterly financial data. Also explore how large is Samsung Pharm's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Samsung Pharm (2012–2024)
The table below shows the annual net assets of Samsung Pharm from 2012 to 2024. For live valuation and market cap data, see Samsung Pharm market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩105.86 Billion ≈ $71.74 Million |
+36.44% |
| 2023-12-31 | ₩77.58 Billion ≈ $52.58 Million |
-24.37% |
| 2022-12-31 | ₩102.59 Billion ≈ $69.52 Million |
-19.39% |
| 2021-12-31 | ₩127.27 Billion ≈ $86.25 Million |
+4.39% |
| 2020-12-31 | ₩121.92 Billion ≈ $82.62 Million |
-14.64% |
| 2019-12-31 | ₩142.83 Billion ≈ $96.79 Million |
+8.48% |
| 2018-12-31 | ₩131.66 Billion ≈ $89.23 Million |
+40.26% |
| 2017-12-31 | ₩93.87 Billion ≈ $63.61 Million |
+13.95% |
| 2016-12-31 | ₩82.38 Billion ≈ $55.83 Million |
+78.17% |
| 2015-12-31 | ₩46.24 Billion ≈ $31.33 Million |
+98.48% |
| 2014-12-31 | ₩23.29 Billion ≈ $15.79 Million |
-32.89% |
| 2012-12-31 | ₩34.71 Billion ≈ $23.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Samsung Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11369932797000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩222.69 Billion | 210.37% |
| Total Equity | ₩105.86 Billion | 100.00% |
Samsung Pharm Competitors by Market Cap
The table below lists competitors of Samsung Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
|
$129.51 Million |
|
Novem Group S.A.
XETRA:NVM
|
$129.52 Million |
|
Wonik Corporation
KQ:032940
|
$129.58 Million |
|
CPI Card Group Inc
NASDAQ:PMTS
|
$129.59 Million |
|
Ba Ria Vung Tau House Development JSC
VN:HDC
|
$129.43 Million |
|
Nordic Halibut AS
OL:NOHAL
|
$129.34 Million |
|
Shanghai Huayi Group Corp Ltd B
SHG:900909
|
$129.33 Million |
|
Kross Ltd
NSE:KROSS
|
$129.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Samsung Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 77,584,546,530 to 105,855,344,770, a change of 28,270,798,240 (36.4%).
- Net loss of 14,092,018,350 reduced equity.
- New share issuances of 39,666,396,100 increased equity.
- Other factors increased equity by 2,696,420,490.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-14.09 Billion | -13.31% |
| Share Issuances | ₩39.67 Billion | +37.47% |
| Other Changes | ₩2.70 Billion | +2.55% |
| Total Change | ₩- | 36.44% |
Book Value vs Market Value Analysis
This analysis compares Samsung Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.80x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.98x to 1.80x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩2074.70 | ₩2030.00 | x |
| 2018-12-31 | ₩2262.51 | ₩2030.00 | x |
| 2019-12-31 | ₩2422.79 | ₩2030.00 | x |
| 2020-12-31 | ₩1788.33 | ₩2030.00 | x |
| 2021-12-31 | ₩1710.78 | ₩2030.00 | x |
| 2022-12-31 | ₩1379.03 | ₩2030.00 | x |
| 2023-12-31 | ₩1042.90 | ₩2030.00 | x |
| 2024-12-31 | ₩1124.68 | ₩2030.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Samsung Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.81%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.21x
- Recent ROE (-13.31%) is above the historical average (-23.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -9.02% | -6.62% | 0.46x | 2.97x | ₩-6.60 Billion |
| 2014 | -101.95% | -78.41% | 0.53x | 2.46x | ₩-26.08 Billion |
| 2015 | -2.15% | -2.36% | 0.32x | 2.82x | ₩-5.62 Billion |
| 2016 | -26.24% | -44.83% | 0.35x | 1.68x | ₩-29.86 Billion |
| 2017 | -8.03% | -17.99% | 0.27x | 1.64x | ₩-16.93 Billion |
| 2018 | -1.58% | -4.47% | 0.29x | 1.22x | ₩-15.24 Billion |
| 2019 | 4.82% | 15.45% | 0.26x | 1.18x | ₩-7.40 Billion |
| 2020 | -32.71% | -82.61% | 0.27x | 1.47x | ₩-52.07 Billion |
| 2021 | -31.65% | -73.36% | 0.38x | 1.14x | ₩-53.00 Billion |
| 2022 | -24.46% | -48.41% | 0.44x | 1.15x | ₩-35.35 Billion |
| 2023 | -31.98% | -47.76% | 0.56x | 1.20x | ₩-32.57 Billion |
| 2024 | -13.31% | -31.81% | 0.34x | 1.21x | ₩-24.68 Billion |
Industry Comparison
This section compares Samsung Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $417,135,058,503
- Average return on equity (ROE) among peers: 2.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Samsung Pharm (001360) | ₩180.09 Billion | -9.02% | 0.24x | $129.48 Million |
| Dongwha Pharm.Co.Ltd (000020) | $296.94 Billion | 15.83% | 0.24x | $113.83 Million |
| Yuhan Corp. (000100) | $756.45 Billion | 11.87% | 0.32x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.61 Trillion | 6.79% | 0.30x | $59.61 Million |
| Yuyu Pharma (000220) | $73.73 Billion | -0.34% | 0.41x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $123.37 Billion | -4.85% | 0.58x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $71.49 Billion | -10.45% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $164.95 Billion | -2.25% | 0.61x | $76.14 Million |
| Samil Pharm (000520) | $65.75 Billion | -8.13% | 2.44x | $127.90 Million |
| Donga Socio Holdings (000640) | $746.90 Billion | 2.65% | 0.82x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Samsung Pharm
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamin… Read more